COMPARATIVE IN-VITRO ACTIVITIES AND POSTANTIBIOTIC EFFECTS OF THE OXAZOLIDINONE COMPOUNDS EPEREZOLID (PNU-100592) AND LINEZOLID (PNU-100766) VERSUS VANCOMYCIN AGAINST STAPHYLOCOCCUS-AUREUS, COAGULASE-NEGATIVE STAPHYLOCOCCI, ENTEROCOCCUS-FAECALIS, AND ENTEROCOCCUS-FAECIUM

The activities of the oxazolidinone antibacterial agents eperezolid (P NU-100592) and linezolid (PNU-100766) were compared with that of vanco mycin against clinical isolates of methicillin-susceptible and -resist ant Staphylococcus aureus (n = 200), coagulase-negative staphylococci (n = 100), and vancomycin-susceptible and -resistant Enterococcus faec alis and Enterococcus faecium (n = 50). Eperezolid and linezolid demon strated good in vitro inhibitory activity, regardless of methicillin s usceptibility for staphylococci (MIC at which 90% of the isolates are inhibited [MIC90] range, 1 to 4 mu g/ml) or vancomycin susceptibility for enterococci (MIC90 range, 1 to 4 mu g/ml). In time-kilt studies, e perezolid and linezolid were bacteriostatic in action. A postantibioti c effect of 0.8 +/- 0.5 h was demonstrated for both eperezolid and lin ezolid against S. aureus, S. epidermidis, E. faecalis, and E. faecium.